v2.4.0.6
Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Revenues:    
Product sales $ 34,357 $ 5,597
Contracts and grants 15,954 12,936
Total revenues 50,311 18,533
Operating expense:    
Cost of product sales 7,511 1,068
Research and development 26,246 34,759
Selling, general and administrative 19,492 18,212
Impairment of in-process research and development 9,600 0
Loss from operations (12,538) (35,506)
Other income (expense):    
Interest income 25 35
Interest expense (3) 0
Other income (expense), net 854 (1)
Total other income (expense) 876 34
Loss before benefit from income taxes (11,662) (35,472)
Benefit from income taxes (3,640) (12,299)
Net loss (8,022) (23,173)
Net loss attributable to noncontrolling interest 1,193 1,776
Net loss attributable to Emergent BioSolutions Inc. $ (6,829) $ (21,397)
Loss per share - diluted $ (0.19) $ (0.61)
Loss per share - basic $ (0.19) $ (0.61)
Weighted-average number of shares - basic 36,045,839 35,179,317
Weighted-average number of shares - diluted 36,045,839 35,179,317